artemether/lumefantrine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   59 Trials   59 Trials   913 News 


«12345678910111213...1516»
  • ||||||||||  Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
    Journal:  Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea. (Pubmed Central) -  Oct 1, 2023   
    The emergence and spread of P. falciparum lineages with both Pfkelch13-mediated partial resistance to artemisinin and deletions in hrp2 and hrp3 in Eritrea threaten to compromise regional malaria control and elimination campaigns. (Funded by the Bill and Melinda Gates Foundation and others; Australian New Zealand Clinical Trials Registry numbers, ACTRN12618001223224, ACTRN12618000353291, and ACTRN12619000859189.).
  • ||||||||||  artemether/lumefantrine / Generic mfg.
    PK/PD data, Journal:  -Pharmacokinetics of drugs used to treat uncomplicated malaria in breastfeeding mother-infant pairs: An observational pharmacokinetic study. (Pubmed Central) -  Sep 25, 2023   
    Artemisinin-based combination therapies (ACTs), primarily artemether-lumefantrine (AL), are the current first-line treatment for uncomplicated Plasmodium falciparum malaria, with the same dosing recommendations in breastfeeding women as those in the adult population...Pharmacokinetic data will be analyzed using a population pharmacokinetic approach. We anticipate that findings from this research will guide to develop a PK model describing lumefantrine and piperaquine disposition and will provide a framework to foster other lactation pharmacokinetic studies in different disease areas.
  • ||||||||||  amodiaquine hydrochloride / Generic mfg., artemether/lumefantrine / Generic mfg.
    32 - Approaching Malaria Elimination in Cambodia: Progress and Challenges (2 Grand Ballroom B - Ballroom Level (East Tower); In-Person) -  Aug 25, 2023 - Abstract #ASTMH2023ASTMH_158;    
    Community engagement has increasingly received attention in malaria research and programme interventions, particularly as countries aim for malaria elimination. We present a novel approach by engaging Cambodian youth to sustain malaria elimination activities and will present their opinions and perspectives via video recordings.
  • ||||||||||  primaquine / Generic mfg., artemether/lumefantrine / Generic mfg.
    Journal:  A Marginal Case of Malaria: An Interesting Malaria Story of Cameroon Origin (Pubmed Central) -  Jul 18, 2023   
    Since P.vivax and P.ovale species were also detected after species determination by molecular methods, primaquine 1 x 30 mg tablet was added to the existing drugs for the treatment of hypnozoite forms of the parasite...When the insecticide-resistant vectors and drug-resistant Plasmodium strains encountered in recent years are evaluated as a whole, there is a need to develop more effective strategies in the fight against malaria. In addition to microscopic examination, which is accepted as the gold standard, we believe that evaluating molecular studies together in diagnosis is extremely important for the treatment process when hypnozoite periods are considered.
  • ||||||||||  artemether/lumefantrine / Generic mfg.
    Journal:  Impact assessment of Intensified Malaria Control Project in transitioning a high malaria-endemic district to a low-endemic district: an epidemiological aspect. (Pubmed Central) -  Jun 14, 2023   
    IMCP activities include introducing bi-valent rapid diagnostic kits (RDTs), Artemether-Lumefantrine drug in North-East India, long-lasting insecticidal nets (LLINs) distribution, and creating awareness programs about malaria in an intensified mode...Udalguri and Khoirabari BPHCs showed an overall reduction of 94% (95%CI: -143%, -45%, p?=?0.001) and 84% (95%CI: -126%, -39%, p?=?0.003), respectively; however, only a 10% (95%CI: -65%, -41%, p?=?0.360) reduction in API was observed in Orang BPHC. An overall decrease in malaria indicates the effective implementation of vector and disease control strategies in the Udalguri district.
  • ||||||||||  artemether/lumefantrine / Generic mfg.
    Clinical, Journal:  Community engagement among forest goers in a malaria prophylaxis trial: implementation challenges and implications. (Pubmed Central) -  Jun 12, 2023   
    The comprehensive, participatory engagement strategy mobilized a wide range of stakeholders including study participants, helped build trust, and overcame potential ethical and practical challenges. This locally-adapted approach was highly effective as evidenced by high levels of trial enrolment, compliance with trial procedures and drug intake.
  • ||||||||||  artemether/lumefantrine / Generic mfg.
    Journal:  Pharmacopeial quality of artemether-lumefantrine anti-malarial agents in Uganda. (Pubmed Central) -  May 31, 2023   
    Artemether-lumefantrine agents, the recommended first-line treatment for uncomplicated malaria with APIs outside the recommended pharmacopeial content assay limit is common especially in high malaria transmission settings. There is need for continuous surveillance and monitoring of the quality of artemisinin-based anti-malarials across the country by the drug regulatory agency.
  • ||||||||||  artemether/lumefantrine / Generic mfg.
    Journal:  Weight-related malaria treatment failure with artemether-lumefantrine. (Pubmed Central) -  May 22, 2023   
    There is need for continuous surveillance and monitoring of the quality of artemisinin-based anti-malarials across the country by the drug regulatory agency. He was diagnosed with uncomplicated malaria and initiated on a three-day course of combined atovaquone (250
  • ||||||||||  artemether/lumefantrine / Generic mfg.
    Journal:  Early effects of COVID-19 on maternal and child health service disruption in Mozambique. (Pubmed Central) -  May 8, 2023   
    All maternal and child health care service indicators that we assessed demonstrated service delivery disruptions (below 10% of the expected counts), with the number of new users of family planing and malaria treatment with Coartem (number of children under five treated) experiencing the largest disruptions...This study offers subnational and granular estimates of service loss that can be useful for health system recovery planning. To our knowledge, it is the first study on the early impacts of COVID-19 on maternal and child health care service utilization conducted in an African Portuguese-speaking country.
  • ||||||||||  Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
    Journal:  Design, Implementation, and Coordination of Malaria Therapeutic Efficacy Studies in Nigeria in 2018. (Pubmed Central) -  May 7, 2023   
    This communication reports best practices adopted to guide its coordination, and lessons learned during in the process, including applying developed standard operating procedures, powering the sample size adequately for each site to report independently, training the investigating team for fieldwork, facilitating stratification of decisions, determining efficiencies derived from monitoring and quality assessment, and optimizing logistics. The planning and coordination of the 2018 TES activities is a model of a consultative process for the sustainability of antimalarial resistance surveillance in Nigeria.
  • ||||||||||  artemether/lumefantrine / Generic mfg.
    PK/PD data, Journal:  Estimation of Pediatric Dosage of Antimalarial Drugs, Using Pharmacokinetic and Physiological Approach. (Pubmed Central) -  Apr 28, 2023   
    Artemether-lumefantrine is one of the fixed dose combination therapies that was approved by the World Health Organization to treat malaria...The physiology at each time point during the growth of a child may influence how the drug is absorbed, gets distributed, metabolized, and eliminated. From the results, there is a very clear need to conduct a clinical study to further verify if the suggested (i.e., 0.34 mg/kg for artemether and 6 mg/kg for lumefantrine) doses could be clinically efficacious.
  • ||||||||||  Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
    COMPARATIVE EFFECT OF FOUR ANTIMALARIAL TREATMENTS ON HAEMATOCRIT IN CHILDREN IN SOUTHWEST OF NIGERIA (STATION 1) -  Apr 21, 2023 - Abstract #ESPID2023ESPID_674;    
    The mean differences (95% CI) in haematocrit from baseline were 4.7 (95% CI = 3.6, 5.8), 4.4 (95% CI = 2.7, 6.0), 3.8 (95% CI = 3.0, 4.7) and 2.4 (95% CI = 0.5, 4.4), for artemether-lumefantrine, artovaquone-proguanil and artesunate-amodiaquine and chloroquine, respectively. Using the general lineal model, repeated measure analysis showed that there were significant differences in the mean haematocrit level over the 28-day follow-up among the four treatment groups (p<0.05).